Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2014 - 2020)
Zevra Therapeutics' (ZVRA) quarterly Non-Current Deferred Tax Liability came in at $18000.0 in Q4 2020, down 96.67% YoY from $540000.0 in Q1 2020, and down 96.67% on a QoQ basis from $540000.0 in Q4 2019.
Zevra Therapeutics (ZVRA) Non-Current Deferred Tax Liability (2014 - 2020) Analysis & Trends
Zevra Therapeutics (ZVRA) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $18000.0 in Q4 2020.
- Quarterly Non-Current Deferred Tax Liability fell 96.67% year-over-year to $18000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $18000.0 (down 96.67% YoY) and the FY2020 annual result came in at $18000.0, down 96.67% from the prior year.
- Non-Current Deferred Tax Liability retreated to $18000.0 in Q4 2020, from $540000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $540000.0 in Q4 2019 to a low of $10000.0 in Q4 2018.
- A 5-year average of $183400.0 and a median of $89000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2019 — Non-Current Deferred Tax Liability jumped 5300.0% — and 2020, when it plunged 96.67%.
- Tracing ZVRA's Non-Current Deferred Tax Liability over 5 years: stood at $89000.0 in 2016, then jumped by 192.13% to $260000.0 in 2017, then sank by 96.15% to $10000.0 in 2018, then jumped by 5300.0% to $540000.0 in 2019, then slumped by 96.67% to $18000.0 in 2020.
- The last three Non-Current Deferred Tax Liability figures came in at $18000.0 (Q4 2020), $540000.0 (Q4 2019), and $10000.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 18,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Dec 31, 2019 | 540,000.00 |
| Dec 31, 2019 | 540,000.00 |
| Dec 31, 2018 | 10,000.00 |
| Dec 31, 2018 | 10,000.00 |
| Dec 31, 2017 | 260,000.00 |
| Dec 31, 2017 | 260,000.00 |
| Dec 31, 2016 | 89,000.00 |
| Dec 31, 2016 | 89,000.00 |
| Dec 31, 2015 | 80,000.00 |
| Dec 31, 2015 | 80,000.00 |
| Dec 31, 2014 | 170,000.00 |
| Dec 31, 2014 | 170,000.00 |